Biocon is currently trading at Rs. 449.00, up by 0.70 points or 0.16% from its previous closing of Rs. 448.30 on the BSE.
The scrip opened at Rs. 450.40 and has touched a high and low of Rs. 453.15 and Rs. 446.75 respectively. So far 20,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 514.90 on 19-Sep-2014 and a 52 week low of Rs. 396.50 on 25-Aug-2015.
Last one week high and low of the scrip stood at Rs. 453.40 and Rs. 427.05 respectively. The current market cap of the company is Rs. 8,980.00 crore.
The promoters holding in the company stood at 61.02% while Institutions and Non-Institutions held 19.91% and 19.06% respectively.
Biocon, Asia’s premier biopharmaceuticals company, has inaugurated a world class facility for manufacturing new generation, patient-friendly devices for its insulins portfolio. The 100,000 square feet, state-of-the-art new devices facility set up in Bangalore will enable the company to leverage the country’s manufacturing expertise to develop world-class delivery devices for people with diabetes in India and other parts of the world.
The pharma major has also launched Basalog One, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility. Basalog One, a long acting basal insulin glargine presented as an innovative, pre-filled pen, is the first product to roll out of this facility.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1618.50 |
| Dr. Reddys Lab | 1312.40 |
| Cipla | 1295.00 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2285.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: